Proteins

Product Data Sheet

L-Cystine

Cat. No.: HY-N0394 CAS No.: 56-89-3

Molecular Formula: $C_6H_{12}N_2O_4S_2$

Molecular Weight: 240.3

Target: Endogenous Metabolite; Ferroptosis; ROS Kinase; Keap1-Nrf2

Pathway: Metabolic Enzyme/Protease; Apoptosis; Protein Tyrosine Kinase/RTK; NF-κΒ

-20°C Storage: Powder 3 years

In solvent

4°C 2 years -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro 0.1 M NaOH: 3.33 mg/mL (13.86 mM; ultrasonic and warming and adjust pH to 11 with NaOH and heat to 70°C)

0.1 M HCL: 2.5 mg/mL (10.40 mM; ultrasonic and adjust pH to 2 with HCl)

DMSO: < 1 mg/mL (insoluble or slightly soluble)

H₂O: < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.1615 mL	20.8073 mL	41.6146 mL
	5 mM	0.8323 mL	4.1615 mL	8.3229 mL
	10 mM	0.4161 mL	2.0807 mL	4.1615 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description L-Cystine, the extracellular form of L-Cysteine (HY-Y0337), is a nutritionally dispensable semiessential sulfur-containing amino acid, occurring in proteins of plants and animals. L-Cystine induces Nrf2 protein elevation in a Keap1 (HY-P75897)dependent manner and activates Nrf2 transcription factor. L-cystine can elicit cytoprotection by reducing ROS generation and protecting against oxidant- or doxorubicin-induced apoptosis. The reduced reabsorption of L-Cystine in renal tubules and its poor solubility in urine are the important causes of cystine precipitation and cystine crystal formation eventually leading to kidney stones. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and cystinosis^{[1][2][3][4][5][6]}

IC₅₀ & Target Human Endogenous Metabolite

In Vitro L-Cystine (83 μ M or 200 μ M, 24 h or 72 h) effectively reverses the growth inhibition of both Sulfasalazine (HY-14655) and

Erastin (HY-15763) in hepatocellular carcinoma cell lines $^{[1]}$.
L-Cystine ($0.8 \text{mM}, 4 \text{h}$) induces Nrf2 in a Keap1 (HY-P75897)-dependent manner in HeLa cells ^[6] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay ^[1]

Cell Line:	Huh6 and Huh7 cells	
Concentration:	83 μM or 200 μM	
Incubation Time:	72 h or 24 h	
Result:	The degree of growth inhibition of Huh6 and Huh7 cells was greater in medium containing a physiological L-cystine concentration of 83 μ M than in commercial medium with a concentration of 200 μ M L-cystine.	
Western Blot Analysis ^[6]		
Cell Line:	HeLa cells	
Concentration:	0.2 mM	
Incubation Time:	4 h	
Result:	Was sufficient for producing Nrf2 protein elevation at 0.2 mM in HeLa cells.	
Western Blot Analysis ^[6]		
Cell Line:	HeLa cells	
Concentration:	0.8 mM	
Incubation Time:	4 h	
Result:	Induced Nrf2 in a Keap1 (HY-P75897)-dependent manner in HeLa cells.	

In Vivo

L-Cystine (280 mg/kg, p.o., 11 days) administrated with L-theanine (HY-15121) enhances antigen-specific IgG production partly through augmentation of glutathione (GSH) levels and T helper 2 (Th2)-mediated responses in mice^[2]. L-Cystine (200 mg/kg, p.o., 11 days) administrated with L-theanine (HY-15121) (80 mg/kg, p.o., 11 days) significantly decreases the serum IL-10/IFN- γ ratio 6 hours after antigenic stimulation, but increases the serum IL-10/IFN- γ ratio 24 hours after antigenic stimulation in mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nine-week-old female BALB/c mice ^[2]	
Dosage:	140, 280 and 560 mg/kg	
Administration:	p.o. administration for 11 days	
Result:	Significantly increased IgG and IgM antibody production administrated with L-theanine (HY-15121) at a dose of 280 mg/kg in mice.	

REFERENCES

[1]. Ohtsu I, et al. Uptake of L-cystine via an ABC transporter contributes defense of oxidative stress in the L-cystine export-dependent manner in Escherichia coli. PLoS One. 2015 Apr 2;10(3):e0120619.

Page 2 of 3 www.MedChemExpress.com

- [2]. Abdullah M, et al. Extracellular Concentration of L-Cystine Determines the Sensitivity to System xc- Inhibitors[J]. Biomol Ther (Seoul). 2022 Mar 1;30(2):184-190.
- [3]. Kurihara S, et al. Enhancement of antigen-specific immunoglobulin G production in mice by co-administration of L-cystine and L-theanine[J]. J Vet Med Sci. 2007 Dec;69(12):1263-70.
- [4]. Dominique Bazin, et al. Cystinuria and cystinosis are usually related to L-cystine: is this really the case for cystinosis? A physicochemical investigation at micrometre and nanometre scale. Comptes Rendus. Chimie, Volume 25 (2022) no. S1, pp. 489-502.
- [5]. Greth WE, et al. Cellular accumulation of L-cystine in rat kidney cortex in vivo[J]. J Clin Invest. 1973 Feb;52(2):454-62.
- [6]. Dai W, et al. Fresh Medium or L-Cystine as an Effective Nrf2 Inducer for Cytoprotection in Cell Culture[J]. Cells. 2023 Jan 12;12(2):291.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 3 of 3 www.MedChemExpress.com